The mechanism of Xihuang pills' intervention in the tumour immune microenvironment for the treatment of liver cancer based on the STAT3-PDL1 pathway

肿瘤微环境 免疫系统 癌症 肝细胞癌 免疫疗法 医学 转移 免疫学 细胞因子 肝癌 癌症研究 肿瘤科 药理学 内科学
作者
Sheng Wang,Wenhui Wang,Kai‐Li Liu,Yanzhi Liu,Xiaoyu Shen,Qiule Li,Fanying Deng,Xuliang Hao,Sheng Wang
出处
期刊:Journal of Ethnopharmacology [Elsevier]
卷期号:331: 118278-118278 被引量:1
标识
DOI:10.1016/j.jep.2024.118278
摘要

Xihuang pills, a time-honored Chinese compound formula with a history spanning thousands of years, have demonstrated remarkable efficacy in treating various cancers, such as breast cancer, colon cancer, and liver cancer. Clinical applications over the years have established their effectiveness. Several scholars conducting experimental studies have elucidated the potent tumor-suppressing effects of Xihuang pills. While the inhibition of tumor vascular development and prevention of tumor cell invasion and metastasis have been well-explored mechanisms, the impact on the tumor immune microenvironment has received less attention. This study focuses on investigating the immune microenvironment adjustments induced by Xihuang pills in hepatocellular carcinoma. Tumour cells will find an escape phenomenon during tumour immunotherapy, which will affect immunotherapy results. We will research the regulation of the tumour immune microenvironment, to provide a more complete and precise basis for the elucidation of the mechanism of Xihuang pills in treating cancers.It provides new research ideas for people to treat liver cancer. Through in vivo and in vitro assessments confirming the intervention effects of Xihuang pills, we observed alterations in T cell typing, macrophage polarization, and tumor-associated cytokine levels. The primary active ingredients of Xihuang pills were identified using UPLC-MS/GC-MS, and relevant pathways in the treatment of hepatocellular carcinoma were predicted through network pharmacology. Combining the network pharmacology approach, we predicted the pathways relevant to Xihuang pills in treating hepatocellular carcinoma and experimentally validated the involvement of PD-1/PD-L1, a key immunity-related axis. Xihuang Pill has a regulatory effect on the tumor immune microenvironment. The results indicated that Xihuang pills could impact splenic lymphocyte phenotyping, macrophage polarization, and IL-6 cytokine expression in liver cancer mice.The mechanism of action was associated with the regulation of the PD-1/PD-L1 signaling pathway by the STAT3 protein.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
呱呱发布了新的文献求助30
刚刚
orixero应助尺八采纳,获得10
刚刚
1秒前
1秒前
sara完成签到,获得积分10
1秒前
虚无无需无完成签到,获得积分10
2秒前
微笑惜文完成签到,获得积分10
2秒前
幽芊细雨发布了新的文献求助10
2秒前
wansida完成签到,获得积分10
4秒前
Ava应助卡卡罗特采纳,获得10
6秒前
阿叶同学完成签到,获得积分10
6秒前
健忘的金完成签到,获得积分20
6秒前
kyou发布了新的文献求助10
6秒前
卡曼菊完成签到,获得积分20
6秒前
7秒前
8秒前
8秒前
GOD伟完成签到,获得积分10
8秒前
田様应助虚无无需无采纳,获得50
8秒前
zz完成签到,获得积分10
10秒前
酷波er应助cccc采纳,获得10
10秒前
10秒前
kyfw完成签到 ,获得积分10
11秒前
北风北风完成签到 ,获得积分10
11秒前
哈哈发布了新的文献求助30
12秒前
顾矜应助阜睿采纳,获得10
13秒前
太叔丹翠发布了新的文献求助10
13秒前
14秒前
14秒前
zk完成签到 ,获得积分10
15秒前
sss完成签到,获得积分10
15秒前
llzuo完成签到,获得积分10
16秒前
18秒前
嗯嗯嗯嗯嗯完成签到 ,获得积分10
18秒前
ma完成签到,获得积分10
19秒前
大方马里奥完成签到,获得积分20
20秒前
昭奚完成签到 ,获得积分10
22秒前
gg发布了新的文献求助10
23秒前
23秒前
小马甲应助kyou采纳,获得10
24秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3140765
求助须知:如何正确求助?哪些是违规求助? 2791647
关于积分的说明 7799859
捐赠科研通 2447961
什么是DOI,文献DOI怎么找? 1302261
科研通“疑难数据库(出版商)”最低求助积分说明 626487
版权声明 601194